QCLS · Insider Trading
Q/C Technologies, Inc. Common Stock
Every open-market purchase and sale reported by QCLS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Joshua Silverman | Executive Chairman | A | +94,010 | — |
| 2026-10-02 | Joshua Silverman | Executive Chairman | A | +16,806 | — |
| 2026-05-14 | Chelsea Sierra Voss | Director | Buy | +1,753 | +$5.52K |
| 2026-04-15 | Bruce Bernstein | Director | A | +50,000 deriv. | — |
| 2026-04-15 | Mitchell Glass | Chief Medical Officer | A | +50,000 deriv. | — |
| 2026-04-15 | Billy Joe White | Director | A | +50,000 deriv. | — |
| 2026-04-15 | Joshua Silverman | Executive Chairman | A | +162,162 | — |
| 2026-04-15 | Stephen Friscia | Director | A | +50,000 deriv. | — |
| 2026-04-15 | Chelsea Sierra Voss | Director | A | +50,000 deriv. | — |
| 2026-01-30 | Chelsea Sierra Voss | Director | A | +237,500 | — |
| 2025-11-18 | PharmaCyte Biotech, Inc. | 10%+ Owner | Buy | +1,779,730 deriv. | — |
| 2025-11-17 | Billy Joe White | Director | A | +22,839 | — |
| 2025-11-17 | Mitchell Glass | Director, Chief Medical Off. | A | +11,420 | — |
| 2025-11-14 | Gary M Rauch | — | A | +11,420 | — |
| 2025-11-14 | Joshua Silverman | Executive Chairman | A | +91,356 | — |
| 2025-11-14 | Stephen Friscia | Director | A | +22,839 | — |
| 2025-11-14 | Bruce Bernstein | Director | A | +25,000 | — |
| 2025-10-06 | Gary M Rauch | — | A | +1,080 | — |
| 2025-10-06 | Billy Joe White | Director | A | +2,161 | — |
| 2025-10-06 | Stephen Friscia | Director | A | +2,161 | — |
| 2025-10-06 | Joshua Silverman | Executive Chairman | A | +8,644 | — |
| 2025-10-06 | Mitchell Glass | Director, Chief Medical Off. | A | +1,080 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Chelsea Sierra Voss | Director | 301,455 | $111.51K |
| Joshua Silverman | Executive Chairman | 116,835 | $43.22K |
| Billy Joe White | Director | 25,024 | $9.26K |
| Bruce Bernstein | Director | 25,000 | $9.25K |
| Stephen Friscia | Director | 25,000 | $9.25K |
| Gary M Rauch | — | 12,500 | $4.62K |
| Mitchell Glass | Chief Medical Officer | 12,500 | $4.62K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the QCLS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.